284 related articles for article (PubMed ID: 8690899)
1. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
Palmer LD; Saha B; Hodes RJ; Abe R
J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
[TBL] [Abstract][Full Text] [Related]
2. Concomitant infection with exogenous mouse mammary tumor virus encoding I-E-dependent superantigen in I-E-negative mouse strain.
Ando Y; Wajjwalku W; Niimi N; Hiromatsu K; Morishima T; Yoshikai Y
J Immunol; 1995 Jun; 154(12):6219-26. PubMed ID: 7759859
[TBL] [Abstract][Full Text] [Related]
3. Association of a V beta 2-specific superantigen with a tumorigenic milk-borne mouse mammary tumor virus.
Hodes RJ; Novick MB; Palmer LD; Knepper JE
J Immunol; 1993 Feb; 150(4):1422-8. PubMed ID: 8094408
[TBL] [Abstract][Full Text] [Related]
4. T cells bearing Vbeta8 are preferentially infected with exogenous mouse mammary tumor virus.
Upragarin N; Nishimura H; Wajjwalku W; Ando Y; Nagafuchi S; Watanabe T; Yoshikai Y
J Immunol; 1997 Sep; 159(5):2189-95. PubMed ID: 9278306
[TBL] [Abstract][Full Text] [Related]
5. B and T cells are required for mouse mammary tumor virus spread within the mammary gland.
Golovkina TV; Dudley JP; Ross SR
J Immunol; 1998 Sep; 161(5):2375-82. PubMed ID: 9725233
[TBL] [Abstract][Full Text] [Related]
6. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination.
Champagne E; Scarpellino L; Lane P; Acha-Orbea H
Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566
[TBL] [Abstract][Full Text] [Related]
7. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
Maillard I; Erny K; Acha-Orbea H; Diggelmann H
Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
[TBL] [Abstract][Full Text] [Related]
8. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor V beta 2-transgenic mice.
Gill R; Wang H; Bluethmann H; Iglesias A; Wei WZ
Cancer Res; 1994 Mar; 54(6):1529-35. PubMed ID: 8137259
[TBL] [Abstract][Full Text] [Related]
9. Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression.
Xu L; Wrona TJ; Dudley JP
Virology; 1996 Jan; 215(2):113-23. PubMed ID: 8560758
[TBL] [Abstract][Full Text] [Related]
10. Maternal transfer of infectious mouse mammary tumor retroviruses does not depend on clonal deletion of superantigen-reactive V beta 14+ T cells.
Penninger JM; Wallace VA; Timms E; Mak TW
Eur J Immunol; 1994 May; 24(5):1102-8. PubMed ID: 8181521
[TBL] [Abstract][Full Text] [Related]
11. Mouse mammary tumor virus (MMTV), a retrovirus that exploits the immune system. Genetics of susceptibility to MMTV infection.
Ross SR; Dzuris JL; Golovkina TV; Clemmons WC; van den Hoogen B
Medicina (B Aires); 1997; 57 Suppl 2():34-42. PubMed ID: 9567342
[TBL] [Abstract][Full Text] [Related]
12. T cell receptor V beta repertoire in mice lacking endogenous mouse mammary tumor provirus.
Braun MY; Jouvin-Marche E; Marche PN; MacDonald HR; Acha-Orbea H
Eur J Immunol; 1995 Mar; 25(3):857-62. PubMed ID: 7705418
[TBL] [Abstract][Full Text] [Related]
13. New infectious mammary tumor virus superantigen with V beta-specificity identical to staphylococcal enterotoxin B (SEB).
Luther S; Shakhov AN; Xenarios I; Haga S; Imai S; Acha-Orbea H
Eur J Immunol; 1994 Aug; 24(8):1757-64. PubMed ID: 8056034
[TBL] [Abstract][Full Text] [Related]
14. A V beta 8.2-specific superantigen from exogenous mouse mammary tumor virus carried by FM mice.
Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
Eur J Immunol; 1994 Jul; 24(7):1612-9. PubMed ID: 7913038
[TBL] [Abstract][Full Text] [Related]
15. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.
Gilfillan MC; Noel PJ; Podack ER; Reiner SL; Thompson CB
J Immunol; 1998 Mar; 160(5):2180-7. PubMed ID: 9498756
[TBL] [Abstract][Full Text] [Related]
16. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity.
Papiernik M; do Carmo Leite-de-MoraesM ; Pontoux C; Joret AM; Rocha B; Penit C; Dy M
J Immunol; 1997 May; 158(10):4642-53. PubMed ID: 9144476
[TBL] [Abstract][Full Text] [Related]
17. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor beta-chain variable region.
Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
Virology; 1996 Sep; 223(2):387-91. PubMed ID: 8806576
[TBL] [Abstract][Full Text] [Related]
18. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells.
Luther SA; Maillard I; Luthi F; Scarpellino L; Diggelmann H; Acha-Orbea H
J Immunol; 1997 Sep; 159(6):2807-14. PubMed ID: 9300703
[TBL] [Abstract][Full Text] [Related]
19. Lack of MMTV superantigen presentation in MHC class II-deficient mice.
Beutner U; McLellan B; Kraus E; Huber BT
Cell Immunol; 1996 Mar; 168(2):141-7. PubMed ID: 8640859
[TBL] [Abstract][Full Text] [Related]
20. Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.
Baribaud F; Wirth S; Maillard I; Valsesia S; Acha-Orbea H; Diggelmann H
J Virol; 2001 Aug; 75(16):7453-61. PubMed ID: 11462017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
